These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36427266)

  • 1. Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti-Tumor Immunity in Murine Glioblastoma.
    Lugani S; Halabi EA; Oh J; Kohler RH; Peterson HM; Breakefield XO; Chiocca EAA; Miller MA; Garris CS; Weissleder R
    Adv Mater; 2023 Feb; 35(7):e2208782. PubMed ID: 36427266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
    Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.
    Achyut BR; Angara K; Jain M; Borin TF; Rashid MH; Iskander ASM; Ara R; Kolhe R; Howard S; Venugopal N; Rodriguez PC; Bradford JW; Arbab AS
    Sci Rep; 2017 Oct; 7(1):13754. PubMed ID: 29062041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
    Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
    Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
    Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
    ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia coordinates the spatial landscape of myeloid cells within glioblastoma to affect survival.
    Haley MJ; Bere L; Minshull J; Georgaka S; Garcia-Martin N; Howell G; Coope DJ; Roncaroli F; King A; Wedge DC; Allan SM; Pathmanaban ON; Brough D; Couper KN
    Sci Adv; 2024 May; 10(20):eadj3301. PubMed ID: 38758780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.
    Turco V; Pfleiderer K; Hunger J; Horvat NK; Karimian-Jazi K; Schregel K; Fischer M; Brugnara G; Jähne K; Sturm V; Streibel Y; Nguyen D; Altamura S; Agardy DA; Soni SS; Alsasa A; Bunse T; Schlesner M; Muckenthaler MU; Weissleder R; Wick W; Heiland S; Vollmuth P; Bendszus M; Rodell CB; Breckwoldt MO; Platten M
    Nat Commun; 2023 Feb; 14(1):771. PubMed ID: 36774352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
    Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
    Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.
    Huang B; Zhang J; Zong W; Chen S; Zong Z; Zeng X; Zhang H
    Front Immunol; 2023; 14():994698. PubMed ID: 36923402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.
    Achyut BR; Shankar A; Iskander AS; Ara R; Angara K; Zeng P; Knight RA; Scicli AG; Arbab AS
    Cancer Lett; 2015 Dec; 369(2):416-26. PubMed ID: 26404753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.